Group 1 - Haemonetics Corporation announced its financial results for the first quarter of fiscal year 2026, ending June 28, 2025, which are available on its Investor Relations website [1][2] - The company will host a conference call and webcast on August 7, 2025, at 8:00 a.m. ET to discuss the financial results and answer questions from investors and analysts [1][4] - A replay of the conference call and webcast will be available for one year starting from August 7, 2025, at 11:00 a.m. ET [2] Group 2 - Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency [3] - The company offers innovative solutions for critical medical needs, including hospital technologies, plasma collection technologies, and products for blood centers [3]

Core Viewpoint - Haemonetics Corporation reported strong fourth-quarter fiscal 2025 results with adjusted EPS growth and revenue performance that exceeded estimates, reflecting effective execution of its long-term strategy and adaptation to market trends [11]. Financial Performance - The adjusted EPS for Q4 fiscal 2025 was $1.24, a 37.8% increase year over year, surpassing the Zacks Consensus Estimate by 1.6% [1] - Full-year fiscal 2025 adjusted EPS reached $4.57, up 15.4% year over year [1] - Revenues for Q4 decreased by 3.7% to $330.6 million, but still exceeded the Zacks Consensus Estimate by 1% [2] - Full-year fiscal 2025 revenues totaled $1.36 billion, reflecting a 4% year-over-year increase [2] Segment Performance - Plasma segment revenues were $126.7 million, accounting for 38.3% of total revenues, down 9.1% year over year due to lower sales volumes in North America [3] - Blood Center revenues fell 22.8% to $56 million, primarily due to Whole Blood portfolio rationalization [4] - Hospital segment revenues increased by 12.2% to $147.9 million, driven by new product lines and growth in vascular closure and Blood Management Technologies [5] Margin and Operating Performance - Adjusted gross margin for Q4 was 58.4%, up 715 basis points year over year, attributed to volume growth and pricing benefits [6] - Adjusted operating income was $61.8 million, a 60.9% increase year over year, with an adjusted operating margin of 18.7%, up 751 basis points [7] Financial Position - Cash and cash equivalents at the end of Q4 were $306.8 million, up from $178.8 million a year ago, while long-term debt increased to $921.2 million from $797.6 million [8] - Cumulative net cash flow from operating activities was $181.7 million, remaining flat year over year [9] Future Guidance - For fiscal 2026, the company expects GAAP revenues to decline by 3-6%, with organic revenues anticipated to range from negative 2% to positive 1% compared to fiscal 2024 [10] - Full-year 2026 adjusted EPS is projected to be between $4.70 and $5.00, with the Zacks Consensus Estimate at $4.98 [10]

Core Insights - Haemonetics Corporation announced its financial results for the fourth quarter and fiscal year 2025, which ended on March 29, 2025 [1] - The company will host a conference call and webcast on May 8, 2025, at 8:00 a.m. ET to discuss the results and answer questions from investors and analysts [1][2] - Supplemental tables providing additional information on fiscal 2026 revenue growth guidance have been posted on the Investor Relations website [2] Company Overview - Haemonetics is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency [3] - The company offers innovative solutions for critical medical needs, including hospital technologies, plasma collection technologies, and products for blood centers [3]